Source-grounded facts extracted from Anteris Technologies Global Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stephen Denaro was appointed as Class II Director at Anteris Technologies Global Corp..
“On May 11, 2026 (May 12, 2026 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board.”
Susan Knight was appointed as Class I Director at Anteris Technologies Global Corp..
“On May 11, 2026 (May 12, 2026 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board.”
Anteris Technologies Global Corp. reported financial results for first quarter of 2026.
“today reported financial results for the quarter ended 31 March 2026, and provided a corporate update.”
Anteris Technologies Global Corp. terminated Contribution and Stock Purchase Agreement with v2vmedtech, inc. valued at break fee of $400,000 (effective 2026-04-28).
“On April 28 , 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), notified v2vmedtech, inc. (“v2v”) of its election to discontinue additional development contributions under the Contribution and Stock Purchase Agreement dated April 18, 2023 (the “Agreement”).”
Anteris Technologies Global Corp. entered into Lease with Northcross West Industrial Owner, LLC valued at monthly minimum rent initially of $152,708.63 (effective 2026-04-23).
“On April 23 , 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), entered into a lease agreement (the “Lease”) with Northcross West Industrial Owner, LLC (“Northcross”) for approximately 181,436 square feet of space in an office and warehouse facility located in Brooklyn Park, Minnesota.”
Anteris Technologies Global Corp. issued 15,652,173 shares of Common Stock of common stock to Covidien Group S.à r.l. for purchase price of $5.75 per PIPE Share.
“the Company agreed to issue and sell (the “Private Placement”) to the Investor 15,652,173 shares of Common Stock of the Company (the “PIPE Shares”) at a purchase price of $5.75 per PIPE Share.”
Anteris Technologies Global Corp. entered into Purchase Agreement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc valued at approximately $90.0 million (effective 2026-01-20).
“On January 20, 2026, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc (the “Investor”), pursuant to which the Company agreed to issue and sell (the “Private Placement”) to the Investor 15,652,173 shares of Common Stock of the Company (the “PIPE Shares”) at a purchase price of $5.75 per PIPE Share.”
Anteris Technologies Global Corp. entered into Underwriting Agreement with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein valued at approximately $320 million (effective 2026-01-20).
“On January 20, 2026, Anteris Technologies Global Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (the “Offering”) 34,782,609 shares (the “Firm Stock”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $5.75 per share.”
Anteris Technologies Global Corp. terminated Second Amended and Restated Supply and License Agreement, as amended with 4C Medical Technologies, Inc. (effective 2025-11-26).
“On November 26, 2025, Anteris Technologies Global Corp. (the “Company”) notified 4C Medical Technologies, Inc. (“4C”) that it was not renewing the Second Amended and Restated Supply and License Agreement, as amended (the “Supply Agreement”), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT ® tissue used in 4C’s production of medical devices related to transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company’s related sterilization methods in connection with use of ADAPT ® tissue by 4C in its production of medical devices.”
Anteris Technologies Global Corp. issued 250,000 CDI Warrants of warrant to Evolution Capital Pty Ltd for services as lead manager.
“Evolution Capital Pty Ltd acted as lead manager for the CDI Offering, and will be issued 250,000 CDI Warrants.”
Anteris Technologies Global Corp. issued 2,244,896 Common Stock Warrants to purchase 2,244,896 shares of Common Stock of warrant to certain investors in the Common Stock Offering for issued as part of unit at US$4.90 per unit.
“we agreed to sell 2,244,896 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and accompanying five-year warrants (the “Common Stock Warrants”) to purchase 2,244,896 shares of Common Stock at a price of US$4.90 per share of Common Stock and accompanying Common Stock Warrant (the “Common Stock Offering”)”
Anteris Technologies Global Corp. issued 2,244,896 shares of Common Stock of common stock to certain investors in the Common Stock Offering for US$4.90 per unit (one share of Common Stock and one Common Stock Warrant).
“we agreed to sell 2,244,896 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and accompanying five-year warrants (the “Common Stock Warrants”) to purchase 2,244,896 shares of Common Stock at a price of US$4.90 per share of Common Stock and accompanying Common Stock Warrant (the “Common Stock Offering”)”
David Roberts was appointed as Class III Director at Anteris Technologies Global Corp..
“Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.”
Gregory Moss was appointed as Class I Director at Anteris Technologies Global Corp..
“Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board.”
David St Denis was appointed as Class II director at Anteris Technologies Global Corp..
“On March 5, 2025 (March 6, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately.”
David St Denis was appointed as President at Anteris Technologies Global Corp..
“On March 5, 2025 (March 6, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately.”
Anteris Technologies Global Corp.: Amended and Restated Bylaws adopted, including board authority to amend bylaws, supermajority vote requirement, and advance notice provisions (effective 2024-12-13).
“Also on December 13, 2024, the Company adopted its Amended and Restated Bylaws (the “Restated Bylaws”).”
Anteris Technologies Global Corp.: Second Amended and Restated Certificate of Incorporation containing supermajority vote requirement, no written consent, and advance notice provisions (effective 2024-12-13).
“On December 13, 2024, the Company filed its Second Amended and Restated Certificate of Incorporation (the “Second Amended and Restated Certificate”) with the Secretary of State of the State of Delaware.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.